NCT01850849

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic dermatitis and to healthy subjects.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	LEO 39652 cream
DRUG	cream vehicle

Timeline

• Start date: 2013-05-01
• Primary completion: 2014-11-01
• Completion: 2014-12-01
• First posted: 2013-05-10
• Last updated: 2025-02-24

Locations

2 sites across 1 country: United Kingdom